Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexestrol is a synthetic nonsteroidal estrogen of the stilbestrol group and a hydrogenated derivative of diethylstilbestrol. It acts as an estrogen receptor agonist with strong affinity for estrogen receptors. Historically used for estrogen replacement therapy and in the treatment of hormone-dependent cancers (such as prostate cancer), gynecological disorders (including amenorrhea and dysfunctional uterine bleeding), and menopausal syndrome. Its use in humans has been discontinued due to adverse effects on reproductive health and increased risk of severe side effects such as cancer and metabolic disorders. Hexestrol has also been investigated as a hormonal antineoplastic agent. In research settings it has shown activity inhibiting Lassa virus entry by blocking membrane fusion during viral entry[1][2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexestrol.